机译:具有人源化SCFV(单链可变片段)引发白血病细胞杀伤的新型抗CD19嵌合抗原受体
Department of Hematology Navy General Hospital No. 6 Fucheng Road Haidian District Beijing;
Department of Health Management Navy General Hospital No. 6 Fucheng Road Haidian District;
Department of Respiration Navy General Hospital No. 6 Fucheng Road Haidian District Beijing;
Beijing Immunochina Medical Science &
Technology Co. Ltd. No. 8 Shengmingyuan Road Changping;
Beijing Immunochina Medical Science &
Technology Co. Ltd. No. 8 Shengmingyuan Road Changping;
Department of Hematology Navy General Hospital No. 6 Fucheng Road Haidian District Beijing;
Beijing Immunochina Medical Science &
Technology Co. Ltd. No. 8 Shengmingyuan Road Changping;
机译:人源抗CD19嵌合抗原受体-T细胞疗法在淋巴瘤和白血病患者慢性和分辨乙型肝炎病毒感染中是安全有效的
机译:人源化抗CD19嵌合抗原受体T细胞在复发/难治性急性淋巴细胞白血病中持续治疗疗效
机译:自体抗CD19嵌合抗原受体T细胞的免疫治疗,随后进行异基因造血干细胞移植,显着改善了难治性/复发性B细胞急性淋巴细胞白血病中的无白血病生存率。
机译:用慢病毒载体修饰T淋巴细胞以表达抗CD19嵌合抗原受体(CAR)
机译:CD30-重定向的嵌合抗原受体T细胞通过抗原依赖性和FAS / FASL相互作用靶向胚胎癌
机译:单链可变片段的计算机指导设计提高了嵌合抗原受体的特异性。
机译:通过结合抗CD123和抗CD19嵌合抗原受体T细胞治疗CD19靶向免疫疗法后发生的白血病抗原丢失复发
机译:用VEGF触发的细胞死亡受体杀死前列腺癌细胞和内皮细胞